Introduction and Objective: Youth with type 1 diabetes (T1D) may face emotional distress when T1D management conflicts with social goals (e.g., bolusing in front of peers), which can result in risky behavior (e.g., skipping boluses). To help manage such distress, we adapted an evidence-based emotion regulation (ER) intervention, to be: 1) relevant for youth with T1D; and 2) delivered virtually. The current study tested the feasibility and acceptability of this novel intervention. Methods: Twenty youth (age 12±0.7; grades 6-8; 50% minoritized race/ethnicity; 45% female; 45% public/Medicaid insurance) participated in a non-randomized trial with 3 sequential groups. Feasibility was assessed via time to reach recruitment target (6-8 / group), attendance (≥70% attending ≥70% of the 11 sessions), and completion (≥70% attending 1 of the last 2 sessions). Acceptability was measured via averaged score on post-session (6 items) and post-intervention surveys (16 items across 9 domains). A score ≥3.5 indicated the participant mostly “agreed” or “strongly agreed” the session/intervention was acceptable. Open-ended questions assessed perceived benefits and future applications of the intervention. Results: We met recruitment targets within M=23 days/ group. We sent flyers to 205 youth (6% ineligible, 73% never responded, 8% stopped responding, 2% declined, 10% enrolled). Of 20 consented, 75% attended ≥70% of sessions and completed the intervention. Most session survey respondents rated each session as acceptable (score ≥3.5; M=92%). 93% youth / 94% parents rated the intervention as acceptable (score ≥3.5). 100% of youth and 94% of parents would recommend the intervention. Youth identified ER strategies, education about risks of substance use, and peer validation as most helpful, with several anticipating using learned strategies in the future. Conclusion: This study supports the feasibility and acceptability of an online ER intervention for youth with T1D and represents a crucial step in evaluating this novel behavioral intervention. Disclosure R. Wasserman: None. M. Campbell: None. N. Kahhan: None. N.V. Morales: None. M. Miller: None. J. Corry: None. K.S. Morga: None. C. Houck: None. S.R. Patton: Advisory Panel; Current; Glooko, Inc. S. Gurnurkar: None. Funding American Diabetes Association (11-23-JDFBMH-03)
WASSERMAN et al. (Fri,) studied this question.